Skip to main content
Premium Trial:

Request an Annual Quote

Make Way for MiSeq

While its announcement of a new low-cost sequencing platform caused one blogger to lose some sleep, Illumina has Forbes' Matthew Herper contemplating the consequences of the Life Technologies Ion Personal Genome Machine's new competition within the sequencing market. Like the Ion PGM, Illumina's new machine — the MiSeq — is affordably priced, and could bring sequencing to smaller labs. The Broad Institute's Chad Nusbaum tells Forbes that the MiSeq may be fast enough — Illumina says the machine can "go from purified DNA to analyzed data in as few as eight hours, or to generate in excess of 1 gigabase per run in slightly over a day" — to be used in hospitals in the future. Forbes' Herper adds that unlike the Ion PGM, however, MiSeq is based on exisiting technology — it's a "smaller, faster" HiSeq, he says.

Julia Karow at our sister publication In Sequence has more on MiSeq's specs, and Edward Winnick at GenomeWeb Daily News has additional comments from Illumina CEO Jay Flatley, who spoke about the machine's launch at the JP Morgan Healthcare Conference in San Francisco this week.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.